Logo image of CXX.DE

CLOROX COMPANY (CXX.DE) Stock Fundamental Analysis

FRA:CXX - Deutsche Boerse Ag - US1890541097 - Common Stock - Currency: EUR

146.28  +4.6 (+3.25%)

Fundamental Rating

2

Taking everything into account, CXX scores 2 out of 10 in our fundamental rating. CXX was compared to 9 industry peers in the Household Products industry. Both the profitability and financial health of CXX have multiple concerns. CXX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CXX had positive earnings in the past year.
CXX had positive earnings in each of the past 5 years.
CXX had a positive operating cash flow in each of the past 5 years.
CXX.DE Yearly Net Income VS EBIT VS OCF VS FCFCXX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

1.2 Ratios

Industry RankSector Rank
ROA 7.5%
ROE 83.09%
ROIC 12.18%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CXX.DE Yearly ROA, ROE, ROICCXX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 100 200 300 400

1.3 Margins

Industry RankSector Rank
OM 10.03%
PM (TTM) 6.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CXX.DE Yearly Profit, Operating, Gross MarginsCXX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 10 20 30 40

More info and screens

1

2. Health

2.1 Basic Checks

CXX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for CXX has been increased compared to 1 year ago.
The debt/assets ratio for CXX has remained at the same level compared to a year ago.
CXX.DE Yearly Shares OutstandingCXX.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
CXX.DE Yearly Total Debt VS Total AssetsCXX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B

2.2 Solvency

An Altman-Z score of 3.69 indicates that CXX is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 4.45 is on the high side and indicates that CXX has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 4.45
Debt/FCF N/A
Altman-Z 3.69
ROIC/WACC1.76
WACC6.93%
CXX.DE Yearly LT Debt VS Equity VS FCFCXX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 0.97 indicates that CXX may have some problems paying its short term obligations.
CXX has a Quick Ratio of 0.97. This is a bad value and indicates that CXX is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.54
CXX.DE Yearly Current Assets VS Current LiabilitesCXX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B

More info and screens

3

3. Growth

3.1 Past

CXX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -47.44%.
The Earnings Per Share has been decreasing by -5.31% on average over the past years.
The Revenue has decreased by -3.19% in the past year.
The Revenue has been growing slightly by 3.54% on average over the past years.
EPS 1Y (TTM)-47.44%
EPS 3Y-13.45%
EPS 5Y-5.31%
EPS Q2Q%-2.11%
Revenue 1Y (TTM)-3.19%
Revenue growth 3Y4.58%
Revenue growth 5Y3.54%
Sales Q2Q%-0.06%

3.2 Future

Based on estimates for the next years, CXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.57% on average per year.
CXX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.95% yearly.
EPS Next Y1.79%
EPS Next 2Y14.36%
EPS Next 3Y15.75%
EPS Next 5Y18.57%
Revenue Next Year-1.42%
Revenue Next 2Y0.89%
Revenue Next 3Y1.55%
Revenue Next 5Y1.95%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CXX.DE Yearly Revenue VS EstimatesCXX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2B 4B 6B
CXX.DE Yearly EPS VS EstimatesCXX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 35.59, which means the current valuation is very expensive for CXX.
When comparing the Price/Earnings ratio of CXX to the average of the S&P500 Index (26.31), we can say CXX is valued slightly more expensively.
With a Price/Forward Earnings ratio of 34.99, CXX can be considered very expensive at the moment.
When comparing the Price/Forward Earnings ratio of CXX to the average of the S&P500 Index (22.13), we can say CXX is valued expensively.
Industry RankSector Rank
PE 35.59
Fwd PE 34.99
CXX.DE Price Earnings VS Forward Price EarningsCXX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.69
CXX.DE Per share dataCXX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CXX's earnings are expected to grow with 15.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)19.83
PEG (5Y)N/A
EPS Next 2Y14.36%
EPS Next 3Y15.75%

More info and screens

4

5. Dividend

5.1 Amount

CXX has a Yearly Dividend Yield of 3.19%. Purely for dividend investing, there may be better candidates out there.
Compared to an average S&P500 Dividend Yield of 2.40, CXX pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 3.19%

5.2 History

The dividend of CXX is nicely growing with an annual growth rate of 6.51%!
Dividend Growth(5Y)6.51%
Div Incr YearsN/A
Div Non Decr YearsN/A
CXX.DE Yearly Dividends per shareCXX.DE Yearly Dividends per shareYearly Dividends per share 2021 2022 1 2 3

5.3 Sustainability

123.59% of the earnings are spent on dividend by CXX. This is not a sustainable payout ratio.
CXX's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP123.59%
EPS Next 2Y14.36%
EPS Next 3Y15.75%
CXX.DE Yearly Income VS Free CF VS DividendCXX.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B
CXX.DE Dividend Payout.CXX.DE Dividend Payout, showing the Payout Ratio.CXX.DE Dividend Payout.PayoutRetained Earnings

More info and screens

CLOROX COMPANY

FRA:CXX (8/18/2022, 7:00:00 PM)

146.28

+4.6 (+3.25%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryHousehold Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.02B
Analysts48
Price Target134.34 (-8.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.19%
Yearly Dividend4.64
Dividend Growth(5Y)6.51%
DP123.59%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 35.59
Fwd PE 34.99
P/S 2.54
P/FCF N/A
P/OCF N/A
P/B 32.43
P/tB N/A
EV/EBITDA 21.69
EPS(TTM)4.11
EY2.81%
EPS(NY)4.18
Fwd EY2.86%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS57.66
BVpS4.51
TBVpSN/A
PEG (NY)19.83
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.5%
ROE 83.09%
ROCE N/A
ROIC 12.18%
ROICexc N/A
ROICexgc 25.88%
OM 10.03%
PM (TTM) 6.5%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 4.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.54
Altman-Z 3.69
F-Score5
WACC6.93%
ROIC/WACC1.76
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.44%
EPS 3Y-13.45%
EPS 5Y-5.31%
EPS Q2Q%-2.11%
EPS Next Y1.79%
EPS Next 2Y14.36%
EPS Next 3Y15.75%
EPS Next 5Y18.57%
Revenue 1Y (TTM)-3.19%
Revenue growth 3Y4.58%
Revenue growth 5Y3.54%
Sales Q2Q%-0.06%
Revenue Next Year-1.42%
Revenue Next 2Y0.89%
Revenue Next 3Y1.55%
Revenue Next 5Y1.95%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A